Amendia is continuing its buying spree, saying today it purchased the rights to Sinu-Lok, a novel, minimally invasive rod implant replacement used in thoracolumbar spine surgery.
The device was developed and patented by the Institute for Applied Neuroscience technology accelerator at Charleston, S.C.’s Medical University of South Carolina, according to Marietta, Ga.-based Amendia.
“We are very excited that Amendia recognizes the value of this unique differentiated solution for a real clinical problem in minimally invasive spine surgery and is committing to manufacture and market this procedural solution as soon as possible. This first out-license is a validation of our unique innovation incubator / technology accelerator model, demonstrating our ability to transform ideas into valuable healthcare products and make a difference in patients’ lives. We have reviewed over 100 invention disclosures over the past two-and-a-half years and have activated eight projects, six of which are ready for commercial licensing,” IAN chief development officer Ted Bird said in prepared remarks.
The Sinu-Lok is a sinusoidal curve-shaped titanium rod implant designed for minimally invasive lumbar spinal fusion surgeries.
Standard rod implants have lordotic curvatures which Amendia said can put stress on construct components and can lead to potential false torque or false tightening.
The Sinu-Lok’s sinusoidal curve provides an extended range of axial connection between the screw and rod interface, which the company said alleviates issues found in standard rod implants.
“We are pleased to be the first licensee partner of IAN and will be incorporating the Sinu-Lok technology into our Savannah – T pedicle screw system as a key differentiator for Amendia in minimally invasive spinal fusion procedures. The technology developed and the model set up by the IAN team at MUSC is a great fit with our mission to exceed surgeon and patient expectations by creating balanced solutions with disruptive technologies for medical devices paired with biologics and instrumentation,” Amendia CEO Jeff Smith said in a press release.
In July, Amendia said it acquired New Jersey-based spinal technology company Custom Spine. Amendia did not disclose the details of the acquisition.
The company said the acquisition would further its focus on the spinal market and that Custom Spine’s Pathway articulating vertebral interbody technology was of specific interest to Amendia.
In June, Amendia acquired transforaminal lumbar interbody fusion system assets from SpineSelect. The system assets purchased by Amendia include 2 product families – the Marquise MIS channel system and the Turbo MIS TLIF system, the Marietta, Ga.-based company said.
Amendia gained a total of 20 spinal technology patents from SpineSelect, the company said.
